A major shift is underway in the global diabetes and obesity treatment market as the patent for Semaglutide expires in key markets, including India. The development opens the door for a wave of lower-cost alternatives to blockbuster drugs like Wegovy and Ozempic from Novo Nordisk. As a result, the market is poised for intense competition, with multiple pharmaceutical companies preparing to launch generic versions immediately after the patent expiry on March 20.
Multiple Generic Launches Expected
Industry insiders estimate that 15 to 50 branded generic versions could enter the market. These products are expected to be priced significantly lower than the innovator drugs, making treatment more accessible. At the same time, pharmaceutical companies have already formed strategic partnerships to strengthen market reach. Additionally, companies such as Dr. Reddy’s Laboratories, Sun Pharma, Glenmark Pharmaceuticals, MSN Laboratories, Mankind Pharma, and Alkem Laboratories are also gearing up to enter the segment.
Significant Price Reduction Expected
The entry of generics is likely to disrupt pricing dynamics. Industry estimates suggest that generic versions could be priced 60% lower than innovator products, or even at one-third to one-fifth of the original cost. Consequently, this price drop could expand access to advanced obesity and diabetes treatments across a broader patient base.
Experts Urge Caution on Safety and Use
Despite the optimism, experts have raised concerns about potential risks associated with widespread use of injectable semaglutide. Recently, authorities have cautioned against surrogate advertising of these prescription drugs under the guise of awareness campaigns. There are also concerns about adverse effects, including complications such as pancreatitis.
Sheetal Sapale, Vice-President (Commercial), Pharmarack Technologies, noted that companies are launching multiple brands similar to the innovator products. However, only a limited number of generics currently have regulatory approval in India. She added that companies may differentiate their offerings through innovations such as improved drug delivery devices.
Regulatory Scrutiny and Industry Concerns
Jitendra Chouksey, Founder and CEO of Fittr, has raised concerns about the transparency of the approval process. He had earlier approached the Delhi High Court, seeking greater regulatory oversight. Chouksey warned that increased usage could lead to a rise in hospitalisations and side effects, urging stricter accountability within the healthcare system.
Innovator Responds with Price Cuts and Partnerships
In anticipation of rising competition, Novo Nordisk has already taken proactive steps. The company launched Wegovy in India in June 2025 as a once-weekly injection available in multiple dose strengths. Subsequently, it reduced prices by up to 37% on its starting dose in November. Additionally, Novo partnered with Emcure to introduce another semaglutide brand, while Abbott is preparing to launch its own version in India.
Competitive Landscape Expands in Obesity Segment
The obesity drug market is also heating up with competition from Eli Lilly. Its product Mounjaro (tirzepatide) entered the Indian market earlier and has gained traction. Later, Eli Lilly partnered with Cipla to market the drug under a different brand name at the same price. Notably, Mounjaro has already achieved ₹100 crore in sales in recent months.
Understanding GLP-1 Drugs
Both semaglutide and tirzepatide belong to the GLP-1 receptor agonist class of drugs. These therapies mimic the natural GLP-1 hormone, which helps regulate blood sugar levels by increasing insulin production in response to food intake. As demand for effective obesity and diabetes treatments grows, this class of drugs is expected to play a transformative role in the healthcare landscape.
Outlook: Accessibility vs. Accountability
As reported by thehindubusinessline.com, the expiry of the semaglutide patent marks a turning point for the pharmaceutical industry. While lower-cost generics promise wider accessibility, they also bring challenges around regulation, safety, and responsible usage. Balancing affordability with patient safety will be critical as the next phase of growth unfolds in this high-demand therapeutic segment.
